Seronegative myasthenia gravis: A plasma factor inhibiting agonist‐induced acetylcholine receptor function copurifies with IgM

Annals of Neurology

Volumn 30, Issue 4, 1991, Pages 550-557

  Yamamoto, Takeshi ^a,b   Vincent, Angela ^a   Ciulla, Thomas A ^a,c   Lang, Bethan ^a   Johnston, Irene ^a   Newsom‐Davis, John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JUNTENDO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBACHOL; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; EDROPHONIUM; IMMUNOGLOBULIN M;

ARTICLE; CLINICAL ARTICLE; ELECTROMYOGRAPHY; HUMAN; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

AUTOANTIBODIES; BUNGAROTOXINS; CELL LINE; HUMAN; IMMUNOGLOBULIN M; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; SODIUM; SODIUM CHANNELS; SUPPORT, NON-U.S. GOV'T; TEMPERATURE;

EID: 0026002993     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410300407     Document Type: Article

References (27)

1. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagnostic value
2. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays
3. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact neuromuscular junctions
4. Ultrastructural localisation of the terminal and lytic 9th complement component C9 at the motor endplate in myasthenia gravis
5. Immunology of acetylcholine receptors in relation to myasthenia gravis
6. Myasthenia gravis: biology and treatment
7. The TH. Anti‐acetylcholine receptor antibody in mysthenia gravis. II. Clinical and serological follow‐up of individual patients
8. Seronegative myasthenia gravis
9. Diaphragmatic myasthenia in mother and child
10. Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity
11. Letter to the editor
12. Immunological and pharmacological heterogeneity of α‐bungarotoxin binding sites extracted from TE671 cells
13. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671
14. + flux into TE671 cell line
15. α‐Bungarotoxin and antiacetylcholine receptor antibody binding to the human acetylcholine receptor
16. + ionophore by neurotoxins: an allosteric model
17. Greatly increased autoantibody production in myasthenia gravis by thymocyte suspensions prepared with proteolytic enzymes
18. Changes of structural proteins during the assembly of the head of bacteriophage T4
19. Anti‐acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor of the surface of TE671 cells
20. Antifilamin, antivinculin and antitropomyosin antibodies in myasthenia gravis
21. Experimental autoimmune myasthenia: cellular and humoral immune responses
22. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlates
23. Determination of acetylcholine receptor antibody in myasthenia gravis
24. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities and high titers of antiglycolipid antibodies
25. Peripheral neuropathy associated with monoclonal IgM autoantibody
26. Diagnostic significance of IgG, C3 and C9 at the limb muscle motor end‐plate in minimal myasthenia gravis
27. Measurement of junctional acetylcholine receptors in myasthenia: clinical correlates